CPX-351 Plus Enasidenib for Relapsed AML
CPX-351 Plus Enasidenib for Relapsed AML
Active, not recruiting · NCT03825796 · Registry updated 2023-09-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CPX-351 Plus Enasidenib for Relapsed AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 | 2023-09-28 | NCT03825796 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jazz Pharmaceuticals | 60 |
| Jonsson Comprehensive Cancer Center | 115 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles | United States | 126 |
| University of California Davis Comprehensive Cancer Center | Sacramento | United States | 299 |
| University of California San Diego | San Diego | United States | 17 |